Literature DB >> 6203661

Delayed-release bleomycin. Comparative pharmacology of bleomycin oil suspension and bleomycin in saline.

M L Slevin, V J Harvey, G W Aherne, N K Burton, A Johnston, P F Wrigley.   

Abstract

Experimental and clinical evidence indicates that bleomycin by continuous infusion is superior to intermittent administration. Continuous infusion is less convenient, however. It has been suggested that a suspension of bleomycin in sesame oil, given by IM injection, simulates a continuous infusion. The pharmacokinetics of this formulation have been compared with those of bleomycin in saline following IM injection, in six patients. The pharmacokinetic profiles of the two formulations were similar. The only difference between the profiles was the long terminal half-life at very low concentrations between 12 and 48 h after injection of the oil suspension. This difference is of unknown, but doubtful, clinical significance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203661     DOI: 10.1007/bf00401440

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Bleomycin as a possible synchronizing agent for human tumor cells in vivo.

Authors:  S C Barranco; J K Luce; M M Romsdahl; R M Humphrey
Journal:  Cancer Res       Date:  1973-04       Impact factor: 12.701

2.  The response of human lymphoma cells in vitro to bleomycin and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  B Drewinko; J K Novak; S C Barranco
Journal:  Cancer Res       Date:  1972-06       Impact factor: 12.701

3.  Improved therapeutic index of bleomycin when administered by continuous infusion in mice.

Authors:  B I Sikic; J M Collins; E G Mimnaugh; T E Gram
Journal:  Cancer Treat Rep       Date:  1978-12

4.  Combination chemotherapy in germinal cell tumors.

Authors:  M L Samuels; V J Lanzotti; P Y Holoye; L E Boyle; T L Smith; D E Johnson
Journal:  Cancer Treat Rev       Date:  1976-12       Impact factor: 12.111

5.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics.

Authors:  A Johnston; R C Woollard
Journal:  J Pharmacol Methods       Date:  1983-05

6.  The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension.

Authors:  M L Slevin; E M Piall; A Johnston; D A Levison; G W Aherne; S B Tree; T A Lister
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

7.  [Effect of continuous bleomycin treatment and of oil-suspended bleomycin on experimental tumor growth (author's transl)].

Authors:  M Urano; S Koike; K Ando; N Nesumi; Y Sukuki
Journal:  Jpn J Antibiot       Date:  1976-08

8.  Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer.

Authors:  L H Baker; M I Opipari; H Wilson; R Bottomley; C A Coltman
Journal:  Obstet Gynecol       Date:  1978-08       Impact factor: 7.661

9.  Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration.

Authors:  Y M Peng; D S Alberts; H S Chen; N Mason; T E Moon
Journal:  Br J Cancer       Date:  1980-04       Impact factor: 7.640

10.  Radioimmunoassay of bleomycin in plasma and urine.

Authors:  J D Teale; J M Clough; V Marks
Journal:  Br J Cancer       Date:  1977-06       Impact factor: 7.640

View more
  2 in total

1.  A pharmacokinetic evaluation of IM administration of bleomycin oil suspension.

Authors:  M Davy; E Paus; G Lehne
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

2.  Multivesicular liposomes containing bleomycin for subcutaneous administration.

Authors:  R Roy; S Kim
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.